XOMA Royalty (XOMA) Non-Current Deffered Revenue (2010 - 2026)
XOMA Royalty (XOMA) reported Non-Current Deffered Revenue of $2.9 million for Q1 2026, down 29.97% on a YoY basis from $4.1 million in Q1 2025, and down 10.43% sequentially from $3.2 million in Q4 2025.
XOMA Royalty (XOMA) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Non-Current Deffered Revenue data on file, last reported at $2.9 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 29.97% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (down 29.97% YoY), and the FY2025 full-year result was $3.2 million, down 27.6% from the prior year.
- Non-Current Deffered Revenue declined to $2.9 million in Q1 2026, from $3.2 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $11.3 million in Q1 2022 to a low of $2.9 million in Q1 2026.
- A 5-year average of $6.9 million and a median of $7.0 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue declined 13.59% in 2022 and tumbled 39.04% in 2025, its largest moves.
- Tracing XOMA's Non-Current Deffered Revenue over 5 years: stood at $9.5 million in 2022, then decreased by 24.31% to $7.2 million in 2023, then plunged by 38.99% to $4.4 million in 2024, then decreased by 27.6% to $3.2 million in 2025, then decreased by 10.43% to $2.9 million in 2026.
- Business Quant data shows XOMA's Non-Current Deffered Revenue at $2.9 million in Q1 2026, $3.2 million in Q4 2025, and $3.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 2.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.86 Mn |
| Dec 31, 2025 | 3.19 Mn |
| Jun 30, 2025 | 3.67 Mn |
| Mar 31, 2025 | 4.08 Mn |
| Dec 31, 2024 | 4.41 Mn |
| Sep 30, 2024 | 5.59 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Mar 31, 2024 | 6.70 Mn |
| Dec 31, 2023 | 7.23 Mn |
| Sep 30, 2023 | 7.80 Mn |
| Jun 30, 2023 | 8.45 Mn |
| Mar 31, 2023 | 9.04 Mn |
| Dec 31, 2022 | 9.55 Mn |
| Sep 30, 2022 | 10.38 Mn |
| Jun 30, 2022 | 10.84 Mn |
| Mar 31, 2022 | 11.35 Mn |
| Dec 31, 2021 | 11.69 Mn |
| Sep 30, 2021 | 12.31 Mn |
| Jun 30, 2021 | 12.73 Mn |
| Mar 31, 2021 | 13.13 Mn |